CAMBRIDGE, Mass.--(BUSINESS WIRE)--GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients, today announced the appointment of Leslie Hoyt as Chief Operating Officer. A veteran healthcare operations leader, Hoyt, who most recently served United Health Group (NYSE:UNH) as Senior Vice President at Optum Health, will help GNS scale its operations and strategically navigate its development during a time of tremendous growth for the company.
“Leslie brings an enormous passion for improving the health of individuals and the overall quality of care,” said Colin Hill, CEO and Co-founder of GNS. “Her experience will be an essential asset to GNS, as more of our existing customers, as well as new customers, turn to GNS for solutions to complex problems arising from the transition to value-based care. Health plans, providers and biopharmaceutical companies are seeking deeper and more timely knowledge regarding which patients are likely to progress with disease, and which interventions will result in better outcomes for those patients at a lower total cost of care.”
Hoyt’s more than 30 years of experience encompass managed care, healthcare technology, strategy, business consulting and business development. Prior to Optum, Hoyt was Chief Strategy Officer and Managing Partner at Dovetail Health, a start-up focused on medication non-adherence. Before Dovetail, Hoyt worked in healthcare business and technology consulting as Vice President, US Healthcare Practice Lead for Sapient Corporation, where her client roster included payers, providers and pharmaceutical companies. Prior to Sapient, Hoyt worked for a decade building and leading provider organizations focused on managing the cost and quality of care. Hoyt holds a Master’s degree from Boston University.
“GNS is already very well prepared to thrive in today’s value-based healthcare environment. The company has a 16-year track record and stellar reputation as a pioneer in precision medicine, healthcare big data analytics and machine learning,” said Hoyt. “Many more healthcare stakeholders now have an urgent need to answer questions that can only be answered by leveraging causal machine learning, and GNS is uniquely positioned to answer questions such as: ‘which patients are most likely to progress to type 2 diabetes?’, or 'which patients will benefit most from specific care management programs and specific drug formularies?',” said Hoyt.
About GNS Healthcare
GNS Healthcare applies causal machine learning technology to predict which treatments will work for which patients, improving individual patient outcomes and the health of populations, while reducing costs. The GNS technology is based on its MeasureBase™ data integration architecture and patented REFS™ (Reverse Engineering and Forward Simulation) causal inference and simulation engine. Health plans, bio-pharmaceutical companies, healthcare providers, foundations, academic medical centers, and self-insured employers use these cloud-based solutions to solve pressing and costly problems including metabolic syndrome, medication adherence, end-of-life care, preterm birth, personalized care pathways in specialty care, oncology, and diabetes, new drug target discovery, patient stratification in clinical trials, and more. GNS solutions focus on reducing adverse events, slowing disease progression, and improving therapeutic effectiveness through precision matching that maximizes impact on individual patient health outcomes while reducing wasteful spending and downstream medical costs.
Discovering what works, and for whom.